[1] Liu J, Liang W, Jing W, et al. Countdown to 2030: Eliminating hepatitis B disease,China.Bull World health Organ, 2019, 97(3): 230-238.
[2] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 中国肝脏病杂志(电子版), 2019,11(4): 5-27.
[3] Taneva E, Crooker K, Park SH, et al. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis. Antimicrob Agents Chemother, 2016, 60:1667-1675.
[4] Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther, 2021, 54(9):1134-1149. |
